Since 2021, Raj Bhayadia (PhD), is a fellow of Mildred Scheel Career Center (Mildred-Scheel-Nachwuchszentrum, MSNZ) in Frankfurt and leads a junior research group focused on the Identification of novel therapeutic targets in acute myeloid leukemia. The group’s research focuses on identification of novel targeted therapies by taking an unbiased forward genetic approach and establishing pre-clinical therapeutic options using patient derived xenografts (PDX) models. Going forward, his research promises a new era of precision medicine, based on an evidence-based approach tailored to patient’s unique characteristics.
Raj Bhayadia studied Agriculture (B.Sc., GPUA&T, Uttarakhand, India), Life Sciences (M.Sc., JNU, New-Delhi, India), and graduated with a PhD from the Molecular Medicine PhD program at Hannover Medical School. During his doctoral thesis, he established a causal relationship between age-related changes and vascular damage.
For his postdoctoral training, Raj entered the field of acute myeloid leukemia (AML) and joined the laboratory of Jan-Henning Klusmann where he unravelled the therapeutic potential of micro-RNA 193b. He continued his training in AML as a senior research investigator at the university clinic of Halle (Saale). Here, he established innovative in vivo platforms and tools to study leukemia progression and identification.